{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:18:15Z","timestamp":1772558295047,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10120-025-01706-7","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:56:47Z","timestamp":1767488207000},"page":"357-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors and clinical outcomes associated with leptomeningeal carcinomatosis in gastric cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Seong-Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung-Don","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meesun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaewon","family":"Hyung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungeun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyungeun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-1263","authenticated-orcid":false,"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"1706_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"1706_CR2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197\u2013208.","journal-title":"Lancet"},{"key":"1706_CR3","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330.","journal-title":"N Engl J Med"},{"key":"1706_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, Lonardi S, de la Fouchardi\u00e8re C, Coutzac C, et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N Engl J Med. 2025;393:336\u201348.","journal-title":"N Engl J Med"},{"key":"1706_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1706_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"M-Z Qiu","year":"2024","unstructured":"Qiu M-Z, Oh D-Y, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.","journal-title":"BMJ"},{"key":"1706_CR7","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330:2064\u201374.","journal-title":"JAMA"},{"key":"1706_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P, Bai Y, Ryu M-H, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"1706_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368.","journal-title":"Lancet"},{"key":"1706_CR10","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang Y-J, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341.","journal-title":"Nat Med"},{"key":"1706_CR11","doi-asserted-by":"publisher","first-page":"175883592412294","DOI":"10.1177\/17588359241229428","volume":"16","author":"T Ogata","year":"2024","unstructured":"Ogata T, Narita Y, Oze I, Kumanishi R, Nakazawa T, Matsubara Y, et al. Chronological improvement of survival in patients with advanced gastric cancer over 15 years. Ther Adv Med Oncol. 2024;16:17588359241229428.","journal-title":"Ther Adv Med Oncol"},{"key":"1706_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/1097-0142(19830101)51:1<154::AID-CNCR2820510130>3.0.CO;2-K","volume":"51","author":"CP Kokkoris","year":"1983","unstructured":"Kokkoris CP. Leptomeningeal carcinomatosis: how does cancer reach the pia-arachnoid? Cancer. 1983;51:154\u201360.","journal-title":"Cancer"},{"key":"1706_CR13","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/neuonc\/noac023","volume":"24","author":"SR Lowe","year":"2022","unstructured":"Lowe SR, Wang CP, Brisco A, Whiting J, Arrington J, Ahmed K, et al. Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases. Neuro-oncol. 2022;24:1307\u201317.","journal-title":"Neuro-oncol"},{"key":"1706_CR14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20272","author":"G Nayar","year":"2017","unstructured":"Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017. https:\/\/doi.org\/10.18632\/oncotarget.20272.","journal-title":"Oncotarget"},{"key":"1706_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1023\/A:1006156204385","volume":"43","author":"M Kim","year":"1999","unstructured":"Kim M. Intracranial involvement by metastatic advanced gastric carcinoma. J Neuro-Oncol. 1999;43:59\u201362.","journal-title":"J Neuro-Oncol"},{"key":"1706_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/B:NEON.0000013462.43156.f4","volume":"66","author":"J-L Lee","year":"2004","unstructured":"Lee J-L, Kang Y-K, Kim T-W, Chang H-M, Lee G-W, Ryu M-H, et al. Leptomeningeal carcinomatosis in gastric cancer. J Neuro-Oncol. 2004;66:167\u201374.","journal-title":"J Neuro-Oncol"},{"key":"1706_CR17","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.3748\/wjg.15.5086","volume":"15","author":"SY Oh","year":"2009","unstructured":"Oh SY, Lee S-J, Lee J, Lee S, Kim S-H, Kwon H-C, et al. Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. World J Gastroenterol. 2009;15:5086.","journal-title":"World J Gastroenterol"},{"key":"1706_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10434-999-0771-3","volume":"6","author":"JE York","year":"1999","unstructured":"York JE, Stringer J, Ajani JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. Ann Surg Oncol. 1999;6:771\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1706_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4251\/wjgo.v10.i1.56","volume":"10","author":"P Kountourakis","year":"2018","unstructured":"Kountourakis P, Papamichael D, Haralambous H, Michael M, Nakos G, Lazaridou S, et al. Leptomeningeal metastases originated from esophagogastric junction\/gastric cancer: a brief report of two cases. World J Gastrointest Oncol. 2018;10:56.","journal-title":"World J Gastrointest Oncol"},{"key":"1706_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1706_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","volume":"11","author":"SA Grossman","year":"1993","unstructured":"Grossman SA, Finkelstein D, Ruckdeschel J, Trump D, Moynihan T, Ettinger D. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 1993;11:561\u20139.","journal-title":"J Clin Oncol"},{"key":"1706_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","volume":"48","author":"P Peduzzi","year":"1995","unstructured":"Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48:1503\u201310.","journal-title":"J Clin Epidemiol"},{"key":"1706_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710\u20138.","journal-title":"Am J Epidemiol"},{"key":"1706_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/01.COC.0000018175.95100.D1","volume":"26","author":"Y Lisenko","year":"2003","unstructured":"Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol. 2003;26:165\u201370.","journal-title":"Am J Clin Oncol"},{"key":"1706_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.743873","author":"L Huang","year":"2022","unstructured":"Huang L, Zhao Y, Shi Y, Hu W, Zhang J. Bone metastasis from gastric adenocarcinoma\u2014what are the risk factors and associated survival? A large comprehensive population-based cohort study. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.743873.","journal-title":"Front Oncol"},{"key":"1706_CR26","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.21037\/tcr.2019.09.06","volume":"8","author":"S Guo","year":"2019","unstructured":"Guo S, Shang M-Y, Dong Z, Zhang J, Wang Y, Zheng Z-C, et al. Clinicopathological features and prognostic analysis of signet ring cell gastric carcinoma: a population-based study. Transl Cancer Res. 2019;8:1918\u201330.","journal-title":"Transl Cancer Res"},{"key":"1706_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10120-013-0234-1","volume":"17","author":"K-J Kwon","year":"2014","unstructured":"Kwon K-J, Shim K-N, Song E-M, Choi J-Y, Kim S-E, Jung H-K, et al. Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Gastric Cancer. 2014;17:43\u201353.","journal-title":"Gastric Cancer"},{"key":"1706_CR28","doi-asserted-by":"publisher","first-page":"618477","DOI":"10.3389\/fonc.2021.618477","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang C, Liu R, Zhang W-H, Chen X-Z, Liu K, Yang K, et al. Difference between signet ring cell gastric cancers and non-signet ring cell gastric cancers: a systematic review and meta-analysis. Front Oncol. 2021;11:618477.","journal-title":"Front Oncol"},{"key":"1706_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cncr.30911","volume":"124","author":"N Wang","year":"2018","unstructured":"Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer. 2018;124:21\u201335.","journal-title":"Cancer"},{"key":"1706_CR30","doi-asserted-by":"crossref","unstructured":"Mayor S. Electronic self reporting of symptoms may improve survival in patients with metastatic cancer. BMJ: Br Med J (Online). 2017;357.","DOI":"10.1136\/bmj.j2724"},{"key":"1706_CR31","doi-asserted-by":"crossref","unstructured":"Balitsky AK, Rayner D, Britto J, Lionel AC, Ginsberg L, Cho W, et al. Patient-reported outcome measures in cancer care: an updated systematic review and meta-analysis. JAMA Netw Open. 2024;7:e2424793\u2013e.","DOI":"10.1001\/jamanetworkopen.2024.24793"},{"key":"1706_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMp1611252","volume":"376","author":"E Basch","year":"2017","unstructured":"Basch E. Patient-reported outcomes-harnessing patients\u2019 voices to improve clinical care. N Engl J Med. 2017;376:105\u20138.","journal-title":"N Engl J Med"},{"key":"1706_CR33","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1959\u201372.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1706_CR34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/annonc\/mdp353","volume":"21","author":"T Pie\u0144kowski","year":"2010","unstructured":"Pie\u0144kowski T, Zielinski CC. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol. 2010;21:917\u201324.","journal-title":"Ann Oncol"},{"key":"1706_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","volume":"18","author":"H-J Stemmler","year":"2007","unstructured":"Stemmler H-J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood\u2013brain barrier. Anticancer Drugs. 2007;18:23\u20138.","journal-title":"Anticancer Drugs"},{"key":"1706_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.breast.2005.04.017","volume":"15","author":"HJ Stemmler","year":"2006","unstructured":"Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15:219\u201325.","journal-title":"Breast"},{"key":"1706_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ejca.2003.09.018","volume":"40","author":"E Shmueli","year":"2004","unstructured":"Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer. 2004;40:379\u201382.","journal-title":"Eur J Cancer"},{"key":"1706_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","volume":"17","author":"A Morikawa","year":"2017","unstructured":"Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer. 2017;17:23\u20138.","journal-title":"Clin Breast Cancer"},{"key":"1706_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.breast.2015.11.005","volume":"26","author":"T Kordbacheh","year":"2016","unstructured":"Kordbacheh T, Law WY, Smith IE. Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: a review in the era of trastuzumab. Breast. 2016;26:54\u20138.","journal-title":"Breast"},{"key":"1706_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","volume":"139","author":"F Zagouri","year":"2013","unstructured":"Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat. 2013;139:13\u201322.","journal-title":"Breast Cancer Res Treat"},{"key":"1706_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-8118-10-7","volume":"10","author":"C Coisne","year":"2013","unstructured":"Coisne C, Lyck R, Engelhardt B. Live cell imaging techniques to study T cell trafficking across the blood-brain barrier in vitro and in vivo. Fluids Barriers CNS. 2013;10:7.","journal-title":"Fluids Barriers CNS"},{"key":"1706_CR42","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/ijc.30214","volume":"139","author":"Z Pan","year":"2016","unstructured":"Pan Z, Yang G, He H, Zhao G, Yuan T, Li Y, et al. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study. Int J Cancer. 2016;139:1864\u201372.","journal-title":"Int J Cancer"},{"key":"1706_CR43","first-page":"484","volume":"19","author":"M Chamberlain","year":"2016","unstructured":"Chamberlain M, Junck L, Brandsma D, Soffietti R, Rud\u00e0 R, Raizer J, et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2016;19:484\u201392.","journal-title":"Neuro Oncol"},{"key":"1706_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/CAD.0b013e328329707c","volume":"20","author":"KP Raj","year":"2009","unstructured":"Raj KP, Sanati H, Mehta RS, Zell JA. Need for a new treatment strategy: leptomeningeal carcinomatosis from gastric cancer. Anticancer Drugs. 2009;20:301\u20134.","journal-title":"Anticancer Drugs"},{"key":"1706_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010119","volume":"15","author":"AA Khosla","year":"2023","unstructured":"Khosla AA, Saxena S, Ozair A, Venur VA, Peereboom DM, Ahluwalia MS. Novel therapeutic approaches in neoplastic meningitis. Cancers. 2023;15:119.","journal-title":"Cancers"},{"key":"1706_CR46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","volume":"25","author":"PU Kumthekar","year":"2022","unstructured":"Kumthekar PU, Avram MJ, Lassman AB, Lin NU, Lee E, Grimm SA, et al. A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro-oncol. 2022;25:557\u201365.","journal-title":"Neuro-oncol"},{"key":"1706_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf025","author":"C Fan","year":"2025","unstructured":"Fan C, Hu Y, Teng C, Lv Y, Song X, Shen W, et al. Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study). Neuro-oncol. 2025. https:\/\/doi.org\/10.1093\/neuonc\/noaf025.","journal-title":"Neuro-oncol"},{"key":"1706_CR48","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","volume":"29","author":"IC Glitza Oliva","year":"2023","unstructured":"Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023;29:898\u2013905.","journal-title":"Nat Med"},{"key":"1706_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03744-1","author":"M Preusser","year":"2025","unstructured":"Preusser M, Garde-Noguera J, Garc\u00eda-Mosquera JJ, Gion M, Greil R, Arumi M, et al. Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03744-1.","journal-title":"Nat Med"},{"key":"1706_CR50","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.gie.2017.06.028","volume":"87","author":"EZ Mi","year":"2018","unstructured":"Mi EZ, Mi EZ, di Pietro M, O\u2019Donovan M, Hardwick RH, Richardson S, et al. Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. Gastrointest Endosc. 2018;87:408\u201318.","journal-title":"Gastrointest Endosc"},{"key":"1706_CR51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(22)00700-8","volume":"24","author":"CYC Lee","year":"2023","unstructured":"Lee CYC, Olivier A, Honing J, Lydon A-M, Richardson S, O\u2019Donovan M, et al. Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study. Lancet Oncol. 2023;24:107\u201316.","journal-title":"Lancet Oncol"},{"key":"1706_CR52","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/ijc.70044","volume":"157","author":"J Castillo-Iturra","year":"2025","unstructured":"Castillo-Iturra J, Llach J, Luzko I, Aguilera L, L\u00f3pez-Fern\u00e1ndez A, Cruellas M, et al. Performance of upper gastrointestinal endoscopy in CDH1 germline pathogenic variant carriers: a multicenter study. Int J Cancer. 2025;157:2550\u20137.","journal-title":"Int J Cancer"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01706-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01706-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01706-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:03:31Z","timestamp":1772553811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01706-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01706-7","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The Institutional Review Board of Asan Medical Center approved the study and waived the requirement for informed consent due to its retrospective design and the use of de-identified patient data (IRB No. 2025-0342).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}